The Asia Pacific Molecular Quality Controls Market would witness Market growth of 6.7% CAGR during the forecast period (2022-2028).
The rising adoption of third-party quality controls, the growing number of credentialed clinical laboratories, the growing preference for external quality assessment support, declining sequencing costs, increasing government investment to support genomics projects, increasing demand for personalized medicines, and the rising prevalence of infectious diseases, cancer, and genetic diseases are all driving this Market forward.
The expanding number of licensed clinical laboratories, increasing usage of third-party quality controls, and increasing demands for external quality assessment help are some of the primary drivers driving the Molecular Quality Controls Market forward.
Due to the sheer rising demand for precise and high-quality diagnostics tests, the Asia Pacific molecular quality controls Market is in a solid position. With cancer becoming a more common health issue in the APAC region as a result of aging populations and lifestyle changes, the need for precision oncology has become a significant focus of various authorities in the region, prompting the creation of numerous projects. These initiatives include the K-MASTER (Korean Cancer Precision Medicine Diagnosis and Treatment Enterprise) platform in South Korea and the LC-SCRUM lung cancer genomic screening project in Japan.
Congenica, a diagnostic decision support platform provider, signed with Digital China Health Technologies Cooperation Limited (DCHealth) in September 2018 to launch a genomic drug in the Chinese Market . The rising use of tailored medications for disease treatment based on a patient's genetic information is predicted to boost the molecular quality controls Market in the future years
The China Market dominated the Asia Pacific Molecular Quality Controls Market by Country 2021, and would continue to be a dominant Market till 2028; thereby, achieving a Market value of $18.6 million by 2028. The Japan Market is experiencing a CAGR of 6% during (2022 - 2028). Additionally, The India Market would showcase a CAGR of 7.4% during (2022 - 2028).
Based on Analyte Type, the Market is segmented into Single-analyte Controls and Multi-analyte Controls. Based on Application, the Market is segmented into Infectious Diseases Diagnostics, Oncology Testing, Genetic Testing, and Others. Based on Product, the Market is segmented into Independent Controls and Instrument-specific Controls (PCR, DNA Sequencing & NGS, and Others). Based on End User, the Market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & CROs, Academic & Research Institutes, and Others. Based on countries, the Market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Molecular Quality Controls Market is Projected to reach USD 259.4 Million by 2028, at a CAGR of 6.6%
The Market research report covers the analysis of key stake holders of the Market . Key companies profiled in the report include Grifols, S.A, Abbott Laboratories, Quidel Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Seegene, Inc., Randox Laboratories Limited, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, and Microbiologics, Inc.
By Analyte Type
By Application
By Product
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
